A double-blind randomized study comparing @entity800 and XXXX in treating infective episodes in @entity4595 .

@entity1 @entity1712 @entity390 @entity115 @entity4595 @entity158 @entity800
32 hospitalized adult @entity1 with infective episodes of @entity4595 were enrolled in an ongoing double-blind, placebo-controlled study comparing @entity800 with @entity115 . They were randomized to receive either 200 mg @entity800 or 1 g @entity115 , both t.i.d. orally for ten days. In the @entity800 group (15 @entity1 ), clinical response was excellent (clinical cure) in 11 and fair (clinical improvement or early reinfection) in three @entity1 with one failure. In the @entity115 group (17 @entity1 ), clinical response was excellent in six, fair in five, and poor (treatment failure) in six @entity1 . @entity800 levels at 2 h (day 5) were 2.3 to 8.2 mg/l (mean 3.9 mg/l) for serum and 1.3 to 15 mg/l (mean 4.5 mg/l) for sputum. Sputum: serum ratio was 1.2:1. @entity115 levels at 2 h were 10 to 40 mg/l (mean 19.9 mg/l) for serum and 0 to 1.5 mg/l (mean 0.3 mg/l) for sputum, with no @entity115 detected in sputum in 10 of 17 patients. Sputum: serum ratio was 0.02:1. One @entity1 in the @entity800 group had @entity390 . In the @entity115 group, four @entity1 had @entity390 and @entity158 , one had vertigo and one had transient peripheral @entity1712 . @entity800 thus yielded higher sputum concentration and appeared to be more effective and better tolerated than @entity115 in infective episodes of @entity4595 .
